GlobalData on MSN3d
Supernus’s stock sinks after depression drug fails trial
Supernus Pharmaceutical’s stock declined following the release of disappointing Phase IIb trial results for SPN-820, an ...
Supernus Pharmaceuticals Stock Falls On Disappointing Data From Treatment-Resistant Depression Trial
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) revealed the topline data from the Phase 2b study of SPN-820 in adults with ...
BioSpace2d
Supernus Falls Back on CNS Portfolio as Depression Drug Fails Mid-Stage Study
After SPN-820's failure, Supernus is relying on its non-stimulant ADHD drug Qelbree and the recently approved Parkinson’s ...
Fintel on MSN2d
Cantor Fitzgerald Downgrades Supernus Pharmaceuticals (SUPN)
Fintel reports that on February 19, 2025, Cantor Fitzgerald downgraded their outlook for Supernus Pharmaceuticals ...
Supernus Pharmaceuticals, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - SUPN
NEW YORK, NY / ACCESS Newswire / February 21, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus ...
pharmaphorum3d
Supernus reports less than super data for depression drug
Faster-acting drugs have long been sought to protect people with severe depression who may be at risk of self-harm or suicide ...
FierceBiotech3d
Options shrink for Supernus depression drug candidate after key trial failure
Supernus Pharmaceuticals may have had a potential path forward for its depression drug candidate cut off after the asset ...
Supernus plunges on trial setback for depression therapy; Cantor downgrades
Supernus Pharmaceuticals (NASDAQ:SUPN) stock drops as depression candidate SPN-820 misses main goals in Phase 2b trial. Read more here.
The Pharma Letter2d
Depression failure sends Supernus shares downwards
US CNS specialist Supernus Pharmaceuticals has announced that its Phase IIb study of SPN-820 in adults with ...
Supernus' depression treatment fails mid-stage trial, shares plunge
Supernus Pharmaceuticals said on Tuesday its depression treatment trial failed to meet the main goal of reduction in depressive symptoms, sending its shares down 22% aftermarket.
Supernus' Shares Fall 22% After Depression Study Misses Endpoint
Shares of Supernus slid after the company it failed to meet the primary endpoint in its Phase 2b study of SPN-820 in adults with treatment resistant depression.
Supernus Pharmaceuticals (NASDAQ:SUPN) Lowered to Neutral Rating by Cantor Fitzgerald
Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) was downgraded by equities research analysts at Cantor Fitzgerald from an “overweight” rating to a “neutral” rating in a research report issued ...